Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2017 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)

NEW YORK, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
November 09, 2017 16:01 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Third Quarter 2017 Financial Results

NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
November 01, 2017 09:02 ET | Source: Stemline Therapeutics, Inc.

Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting

NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
October 31, 2017 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint

Detailed results will be presented at the ASH 2017 Annual Meeting (Dec. 9-12)Based on FDA feedback, BLA filing remains on-track Conference call scheduled for today, Tuesday, October 31, 2017 at 8:30AM...
September 20, 2017 07:00 ET | Source: Stemline Therapeutics

Stemline Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
September 11, 2017 07:00 ET | Source: Stemline Therapeutics

Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017

NEW YORK, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
September 08, 2017 07:30 ET | Source: Stemline Therapeutics

Stemline Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

NEW YORK, Sept. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
August 30, 2017 18:10 ET | Source: Stemline Therapeutics

Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress

NEW YORK, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
August 14, 2017 07:30 ET | Source: Stemline Therapeutics

Stemline Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
August 08, 2017 07:00 ET | Source: Stemline Therapeutics

Stemline Therapeutics Reports Second Quarter 2017 Financial Results

NEW YORK, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right